[CH3:1][O:2][C:3]1[CH:28]=[CH:27][C:6]([CH2:7][N:8]2[C:12]3[N:13]=[CH:14][C:15]4[CH2:24][CH2:23][C:22]5[N:21]=[C:20](SC)[N:19]=[CH:18][C:17]=5[C:16]=4[C:11]=3[CH:10]=[N:9]2)=[CH:5][CH:4]=1.[OH:29][S:30]([O-:33])(=O)=O.OS(O[O-])(=O)=O.OS(O[O-])(=O)=O.[O-]S([O-])(=O)=O.[K+].[K+].[K+].[K+].[K+].[CH3:56]O.O>>[CH3:1][O:2][C:3]1[CH:4]=[CH:5][C:6]([CH2:7][N:8]2[C:12]3[N:13]=[CH:14][C:15]4[CH2:24][CH2:23][C:22]5[N:21]=[C:20]([S:30]([CH3:56])(=[O:33])=[O:29])[N:19]=[CH:18][C:17]=5[C:16]=4[C:11]=3[CH:10]=[N:9]2)=[CH:27][CH:28]=1To a suspension of 3-(4-methoxybenzyl)-9-(methylsulfanyl)-6,7-dihydro-3H-pyrazolo[4′,3′:5,6]pyrido[4,3-f]quinazoline (1.9 g, 4.8 mmol) in 2:1 mixture of methanol-water (100 mL) was added potassium monopersulfate triple salt (Oxone®, 9.2 g, 15 mmol) and the suspension stirred for 18 hours. On completion of the reaction, the mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate (200 mL) and washed with water (2×20 mL), dried using anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give the desired product, 3-(4-methoxybenzyl)-9-(methylsulfonyl)-6,7-dihydro-3H-pyrazolo[4′,3′:5,6]pyrido[4,3-f]quinazoline (1.5 g, 77%) as a tan solid. LCMS [M+H]: 422. The compound was used without any further purification.